Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: Insights of the mechanism of action

Journal of Drug Targeting

Volumn 15, Issue 7-8, 2007, Pages 518-530

  Zalipsky, Samuel ^a   Saad, Maha ^b   Kiwan, Radwan ^a   Ber, Elizabeth ^b   Yu, Ning ^a   Minko, Tamara ^b  

^a ALZA CORPORATION   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Apoptosis; Enhanced permeability and retention (EPR) effect; Liposomal prodrug of Mitomycin C; Multidrug resistance (MDR); STEALTH liposome (SL); Thioredoxin

Indexed keywords

BETA ACTIN; CASPASE; CASPASE 9; DOXORUBICIN; GLYCEROPHOSPHOETHANOLAMINE; GLYCOPROTEIN P; LIPOSOME; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLCHOLINE; PLACEBO; PROCASPASE 9; PROTEIN BAX; PROTEIN BCL 2; STEALTH; THIOREDOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG STRUCTURE; DRUG TUMOR LEVEL; ENZYME ACTIVATION; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT OUTCOME; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, NUDE; MITOMYCIN; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PERMEABILITY; PRODRUGS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 34547679654     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860701499946     Document Type: Article

References (49)

1. Angelini, G., Gardella, S., Ardy, M., Ciriolo, MR, Filomeni, G., Trapani, G Di, Clarke, F., Sitia, R. and Rubartelli, A. (2002) Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci USA, 99, pp. 1491-1496.
2. Baban, DF and Seymour, LW (1998) Control of tumour vascular permeability. Adv Drug Deliv Rev, 34, pp. 109-119.
3. Baker, AF, Dragovich, T., Tate, WR, Ramanathan, RK, Roe, D., Hsu, CH, Kirkpatrick, DL and Powis, G. (2006) The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med, 147, pp. 83-90.
4. Biaglow, JE and Miller, RA (2005) The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy. Cancer Biol Ther, 4, pp. 6-13.
5. Crenesse, D., Laurens, M., Heurteaux, C., Cursio, R., Saint-Paul, MC, Schmid-Alliana, A. and Gugenheim, J. (2003) Rat liver ischemia-reperfusion-induced apoptosis and necrosis are decreased by FK506 pretreatment. Eur J Pharmacol, 473, pp. 177-184.
6. Dharap, SS, Wang, Y., Chandna, P., Khandare, JJ, Qiu, B., Gunaseelan, S., Sinko, PJ, Stein, S., Farmanfarmaian, A. and Minko, T. (2005) Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci USA, 102, pp. 12962-12967.
7. Dharap, SS, Chandna, P., Wang, Y., Khandare, JJ, Qiu, B., Stein, S. and Minko, T. (2006) Molecular targeting of BCL2 and BCLXL proteins by synthetic BH3 peptide enhances the efficacy of chemotherapy. J Pharmacol Exp Ther, 316, pp. 992-998.
8. Fang, J., Sawa, T. and Maeda, H. (2003) Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol, 519, pp. 29-49.
9. Gabizon, AA, Shmeeda, H. and Zalipsky, S. (2006) Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res, 16, pp. 175-183.
10. Gabizon, AA, Tzemach, D., Horowitz, AT, Shmeeda, H., Yeh, J. and Zalipsky, S. (2006) Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin Cancer Res, 12, pp. 1913-1920.
11. Guo, X. and Szoka Jr, FC (2001) Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate. Bioconjug Chem, 12, pp. 291-300.
12. Hsia, TC, Lin, CC, Wang, JJ, Ho, ST and Kao, A. (2002) Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung, 180, pp. 173-179.
13. Hwang, CY, Ryu, YS, Chung, MS, Kim, KD, Park, SS, Chae, SK, Chae, HZ and Kwon, KS (2004) Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1. Oncogene, 23, pp. 8868-8875.
14. Ihnat, MA, Nervi, AM, Anthony, SP, Kaltreider, RC, Warren, AJ, Pesce, CA, Davis, SA, Lariviere, JP and Hamilton, JW (1999) Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice. Oncol Res, 11, pp. 303-310.
15. Khandare, JJ, Chandna, P., Wang, Y., Pozharov, VP and Minko, T. (2006) Novel polymeric prodrug with multivalent components for cancer therapy. J Pharmacol Exp Ther, 317, pp. 929-937.
16. Kinnula, VL, Paakko, P. and Soini, Y. (2004) Antioxidant enzymes and redox regulating thiol proteins in malignancies of human lung. FEBS Lett, 569, pp. 1-6. 2004
17. Kratz, F., Warnecke, A., Scheuermann, K., Stockmar, C., Schwab, J., Lazar, P., Druckes, P., Esser, N., Drevs, J., Rognan, D., Bissantz, C., Hinderling, C., Folkers, G., Fichtner, I. and Unger, C. (2002) Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem, 45, pp. 5523-5533.
18. Lasic, D. and Martin, F. (1995) STEALTH® Liposomes, CRC press, Boca Raton, FL
19. Lee, Y., Vassilakos, A., Feng, N., Avolio, T., Jin, H., Viau, S., Wang, M., Courssaris, B., Xiong, K., Wright, J. and Young, A. (2006) Anti-proliferative and anti-tumor effects of antisense oligonucleotide GTI-2601 targeted against human thioredoxin. Anticancer Drugs, 17, pp. 143-154.
20. Lincoln, DT, Emadi, EM Ali and Tonissen, KF (2003) The thioredoxin-thioredoxin reductase system: Over-expression in human cancer. Anticancer Res, 23, pp. 2425-2433.
21. Maeda, H. (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul, 41, pp. 189-207.
22. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res, 46, pp. 6387-6392.
23. Minko, T., Kopeckova, P., Pozharov, V. and Kopecek, J. (1998) HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release, 54, pp. 223-233.
24. Minko, T., Kopeckova, P. and Kopecek, J. (1999) Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm Res, 16, pp. 986-996.
25. Minko, T., Kopeckova, P. and Kopecek, J. (1999) Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J Control Release, 59, pp. 133-148. 59
26. Minko, T., Kopeckova, P. and Kopecek, J. (2000) Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer, 86, pp. 108-117.
27. Minko, T., Kopeckova, P., Pozharov, V., Jensen, KD and Kopecek, J. (2000) The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors. Pharm Res, 17, pp. 505-514.
28. Minko, T., Pakunlu, RI, Wang, Y., Khandare, JJ and Saad, M. (2006) New generation of liposomal drugs for cancer. Anticancer Agents Med Chem, 6, pp. 537-552.
29. Nakamura, H., Bai, J., Nishinaka, Y., Ueda, S., Sasada, T., Ohshio, G., Imamura, M., Takabayashi, A., Yamaoka, Y. and Yodoi, J. (2000) Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev, 24, pp. 53-60.
30. Nguyen, P., Awwad, RT, Smart, DD, Spitz, DR and Gius, D. (2006) Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett, 236, pp. 164-174.
31. Pakunlu, RI, Wang, Y., Tsao, W., Pozharov, V., Cook, TJ and Minko, T. (2004) Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: Novel multicomponent delivery system. Cancer Res., 64, pp. 6214-6224.
32. Pakunlu, RI, Wang, Y., Saad, M., Khandare, JJ, Starovoytov, V. and Minko, T. (2006) In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release, 114, pp. 153-162.
33. Powis, G., Mustacich, D. and Coon, A. (2000) The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med, 29, pp. 312-322.
34. Powis, G., Wipf, P., Lynch, SM, Birmingham, A. and Kirkpatrick, DL (2006) Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol Cancer Ther, 5, pp. 630-636.
35. Sato, N., Iwata, S., Nakamura, K., Hori, T., Mori, K. and Yodoi, J. (1995) Thiol-mediated redox regulation of apoptosis. Possible roles of cellular thiols other than glutathione in T cell apoptosis. J Immunol, 154, pp. 3194-3203.
36. Senter, P., Pierce, W. and Greenfield, R. (1990) Development of drug release strategy based on the reductive fragmentation of benzyl carbamate disulfide. J Org Chem, 55, pp. 2975-2978.
37. Sharma, R., Awasthi, YC, Yang, Y., Sharma, A., Singhal, SS and Awasthi, S. (2003) Energy dependent transport of xenobiotics and its relevance to multidrug resistance. Curr Cancer Drug Targets, 3, pp. 89-107.
38. Soderberg, A., Sahaf, B. and Rosen, A. (2000) Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: Presence in human plasma. Cancer Res, 60, pp. 2281-2289.
39. Streicher, KL, Sylte, MJ, Johnson, SE and Sordillo, LM (2004) Thioredoxin reductase regulates angiogenesis by increasing endothelial cell-derived vascular endothelial growth factor. Nutr Cancer, 50, pp. 221-231.
40. Szakacs, G., Jakab, K., Antal, F. and Sarkadi, B. (1998) Diagnostics of multidrug resistance in cancer. Pathol Oncol Res, 4, pp. 251-257.
41. Szoka Jr, FC (1990) The future of liposomal drug delivery. Biotechnol Appl Biochem, 12, pp. 496-500.
42. Torchilin, VP (2000) Drug targeting. Eur J Pharm Sci, 11, pp. S81-S91.
43. van Veen, HW and Konings, WN (1998) The ABC family of multidrug transporters in microorganisms. Biochim Biophys Acta, 1365, pp. 31-36.
44. Vicent, MJ and Duncan, R. (2006) Polymer conjugates: Nanosized medicines for treating cancer. Trends Biotechnol, 24, pp. 39-47.
45. Wang, Y. and Minko, T. (2004) A novel cancer therapy: Combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug. Biochem Pharmacol, 68, pp. 2031-2042.
46. Welsh, SJ, Bellamy, WT, Briehl, MM and Powis, G. (2002) The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res, 62, pp. 5089-5095.
47. Working, P., Newman, M., Huang, S., Mayhew, E., Vaage and Lasic, D. (1994) Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in STEALTH® liposomes (DOXIL). J Liposome Res, 4, pp. 667-687.
48. Xiong, XB, Huang, Y., Lu, WL, Zhang, X., Zhang, H., Nagai, T. and Zhang, Q. (2005) Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release, 107, pp. 262-275.
49. Zalipsky, S., Kiwan, R., Qazen, M., Flaherty, T., Engbers, C., Guo, L., Zomorodi, K., Feng, W., Yeh, J., Horowits, A., Indap, M. and Gabizon, A. (2001) New lipsomal prodrug of mitomycin C. Int'l Symp Control Rel Biact Mater, 2001, pp. 437-438.